Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 4,247 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Meniscectomy, Osteoarthritis
Interventions: NUsurface® Meniscus Implant, NSAID's and Non-surgical Treatment Options, Intra-Articular Injections with Corticosteroids, Intra-Articular Injections with Hyaluronic Acid (HA); Device · Drug
Lead sponsor: Phoenix Kinetics; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 9
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Roxbury Crossing, Massachusetts + 6 more

Conditions: Healthy
Interventions: Acidform 5 g, Placebo 4 g, Acidform 4 g, Acidform 3 g; Drug
Lead sponsor: Evofem Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Enzalutamide, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 65
States / cities: Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 34 more

Conditions: Epilepsy
Interventions: Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category; Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Honolulu, Hawaii • Boise, Idaho • Voorhees Township, New Jersey + 3 more

Conditions: Alzheimer's Disease
Interventions: Bexarotene, Placebo; Drug
Lead sponsor: ReXceptor, Inc.; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Obsessive Compulsive Disorder
Interventions: Minocycline, Placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 8 Years to 20 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]); Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Atrial Fibrillation, Obstructive Sleep Apnea
Interventions: Delayed enhancement magnetic resonance imaging (DE-MRI); Device
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: New Orleans, Louisiana

Conditions: Endometriosis
Interventions: 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate; Drug
Lead sponsor: Main Line Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Wynnewood, Pennsylvania

Conditions: Chronic Gastrointestinal Graft vs Host Disease
Interventions: orBec, Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Hackensack, New Jersey • Buffalo, New York • Nashville, Tennessee

Conditions: PONV
Interventions: APD421- Amisulpride for IV injection, Placebo; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Adenoma, Colorectal Carcinoma
Interventions: Celecoxib, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Psoriasis
Interventions: Drug: LYC-30937-EC, Placebo; Drug
Lead sponsor: Lycera Corp.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Carmel, Indiana • Andover, Massachusetts • Fridley, Minnesota + 4 more

Conditions: Leg Cramp, Nocturnal
Interventions: Theraworx, Placebo; Device · Other
Lead sponsor: Sport and Spine Rehab Clinical Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Insomnia (moderate)
Interventions: GABA Probiotic Lactiplantibacillus plantarum Lp815 (5 Billion cfu/dose), Placebo, Optional Sub-Study: Neurotransmitter Urine Test; Dietary Supplement · Other · Diagnostic Test
Lead sponsor: Verb Biotics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alzheimer's Disease
Interventions: Dimebon, Placebo; Drug
Lead sponsor: Medivation, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 28
States / cities: Phoenix, Arizona • Costa Mesa, California • Fresno, California + 25 more

Conditions: Celiac Disease
Interventions: Placebo, TAK-101, Gluten; Drug · Dietary Supplement
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 26
States / cities: Scottsdale, Arizona • Escondido, California • Poway, California + 17 more

Conditions: Infection Control
Interventions: Enhanced cleaning of surfaces in ICU rooms, Sham enhanced cleaning of surfaces in ICU rooms; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fatigue
Interventions: Methylphenidate, Fatigue Evaluations; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Narcolepsy
Interventions: SEP363856, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL); Drug
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: Beverly Hills, California • Huntington Beach, California • Longmont, Colorado + 11 more

Conditions: Hyperphosphatemia, Anemia, Iron Deficiency, Renal Insufficiency
Interventions: Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Anchorage, Alaska • Mesa, Arizona • Pine Bluff, Arkansas + 6 more

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712 + ADT, Placebo + ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 826 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 37
States / cities: Arcadia, California • Beverly Hills, California • Fresno, California + 34 more

Conditions: COVID-19
Interventions: VIR-7831, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 74
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more

Search by objective public record fields.

Verifying the Effectiveness of the NUsurface® System

Duration of Effect of Acidform Gel on Vaginal pH

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy

A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects

Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Atrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

US Phase III Study of APD421 in PONV

Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

Effect of Theraworx/[pH]Uel on Night-time Leg Cramps and Spasm Symptoms

Impact of GABA Probiotic Lactiplantibacillus Plantarum Lp815 on Sleep Outcomes in Participants with Self-Reported Sleep Disturbance

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria

Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate

This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)